Evidence map›Paper›PMID 39041435›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Harmonizing tau positron emission tomography in Alzheimer's disease: The CenTauR scale and the joint propagation model.

Antoine Leuzy, Lars Lau Raket, Victor L Villemagne, Gregory Klein, Matteo Tonietto, Emily Olafson, Suzanne Baker, Ziad S Saad, Santiago Bullich, Brian Lopresti and 40 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Dynamic [Molecular neurodegeneration · 2026
    Article
  5. Article
  6. Article
  7. Complex interplay of astrogliosis and pathology in preclinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  8. Off-target binding ofAnnals of nuclear medicine · 2026
    Article
  9. Article
  10. Article
  11. Staging Alzheimer's disease through amyloid and tau PET.Brain : a journal of neurology · 2026
    Article
  12. Review
  13. Review
  14. Distinct Tau PET Dynamics in Early vs. Late Age-of-Onset Alzheimer's disease.medRxiv : the preprint server for health sciences · 2026
    Article
  15. Review
  16. Robust Topographical Representation for Longitudinal Propagation of Tau Pathology.Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention · 2026
    Article
  17. Review
  18. Article
  19. Quantitation of PET spatial extent as a potential adjunct to visual interpretation of [European journal of nuclear medicine and molecular imaging · 2025
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors.

Antoine LeuzyClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.
Lars Lau RaketClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.
Victor L VillemagneDepartment of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Gregory KleinF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Matteo ToniettoF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Emily OlafsonClinical Imaging Group, Genentech, Inc., South San Francisco, California, USA.
Suzanne BakerLawrence Berkeley National Laboratory, Berkeley, California, USA.
Ziad S SaadJanssen Research & Development, Merryfield Row San Diego, California, USA.
Santiago BullichLife Molecular Imaging GmbH, Berlin, Germany.
Brian LoprestiDepartment of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Sandra Sanabria BohorquezClinical Imaging Group, Genentech, Inc., South San Francisco, California, USA.
Mercè BoadaAce Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Barcelona, Spain.
Tobey J BetthauserWisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.
Arnaud CharilEisai, Inc., Nutley, New Jersey, USA.
Emily C CollinsEli Lilly and Company, Indianapolis, Indiana, USA.
Jessica A CollinsBiogen, Cambridge, Massachusetts, USA.
Nicholas CullenCritical Path for Alzheimer's Disease (CPAD) Consortium, Critical Path Institute, Tucson, Arizona, USA.
Roger N GunnInvicro, Hammersmith Hospital, London, UK.
Makoto HiguchiDepartment of Functional Brain Imaging, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Inage-ku, Chiba-shi, Chiba, Japan.
Eric HostetlerMerck & Co., Inc, West Point, Pennsylvania, USA.
R Matthew HutchisonBiogen, Cambridge, Massachusetts, USA.
Leonardo IaccarinoEli Lilly and Company, Indianapolis, Indiana, USA.
Philip S InselDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, California, USA.
Michael C IrizarryWisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.
Clifford R JackDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
William J JagustUniversity of California Berkeley, Lawrence Berkeley National Laboratory, Berkeley, California, USA.
Keith A JohnsonHarvard Medical School, Department of Radiology, Boston, Minnesota, USA.
Sterling C JohnsonWisconsin Alzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.
Yashmin KartenCritical Path for Alzheimer's Disease (CPAD) Consortium, Critical Path Institute, Tucson, Arizona, USA.
Marta MarquiéDepartment of Medicine Division of Geriatrics, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.
Sulantha MathotaarachchiEnigma Biomedical Group, Knoxville, Tennessee, USA.
Mark A MintunEli Lilly and Company, Indianapolis, Indiana, USA.
Rik OssenkoppeleClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.
Ioannis PappasDepartment of Psychology, Helen Wills Neuroscience Institute, University of California, Berkeley, California, USA.
Ronald C PetersenDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Gil D RabinoviciDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.
Pedro Rosa-NetoTranslational Neuroimaging Laboratory, Department of Neurology and Neurosurgery, Faculty of Medicine, The McGill University Research Centre for Studies in Aging, McGill University, Verdun, Quebec, Canada.
Christopher G SchwarzDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Ruben SmithClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.
Andrew W StephensLife Molecular Imaging GmbH, Berlin, Germany.
Alex WhittingtonInvicro, Hammersmith Hospital, London, UK.
Maria C CarrilloAlzheimer's Association, Chicago, Illinois, USA.
Michael J PontecorvoEli Lilly and Company, Indianapolis, Indiana, USA.
Samantha Budd HaeberleinEnigma Biomedical Group, Knoxville, Tennessee, USA.
Billy DunnSenior advisor to CPAD Consortium, Critical Path Institute, Tucson, Arizona, USA.
Hartmuth C KolbEnigma Biomedical Group, Knoxville, Tennessee, USA.
Sudhir SivakumaranCritical Path for Alzheimer's Disease (CPAD) Consortium, Critical Path Institute, Tucson, Arizona, USA.
Christopher C RoweFlorey Department of Neuroscience, University of Melbourne, Parkville, Victoria, Australia.
Oskar HanssonClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.
Vincent DoréDepartment of Molecular Imaging & Therapy, Austin Health, Heidelberg, Victoria, Australia.

Funding

Early Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gil Dan Rabinovici · 2019 to 2026
$36.9M
Wisconsin Registry for Alzheimer's Prevention: Sex Differences in DNA MethylationR01AG027161 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Nathaniel Ark Chin, Sterling C Johnson · 2007 to 2026
$35.6M
USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI, ARTHUR W TOGA · 2020 to 2026
$27.8M
The Longitudinal Course of Neural Function and Amyloid in People At Risk for ADR01AG021155 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sterling C Johnson · 2004 to 2026
$27.0M
SV2A PET imaging in Alzheimer's DiseaseR01AG062285 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA, CHRISTIAN, BRADLEY T · 2018 to 2022
$5.3M
Reimagining Precision Medicine Approaches to AD DiagnosisR35AG072362 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI POSSIN, KATHERINE LAUREL, RABINOVICI, GIL DAN · 2021 to 2025
$4.8M
ALF agreement 2022-Projekt0080Alliance for Therapeutics in NeurodegenerationAlzheimer's Association ZEN-21-848216American College of RadiologyCure Alzheimer's fundERA PerMed ERAPERMED2021-184Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS)Knut and Alice Wallenberg foundation 2017-0383Konung Gustaf V:s och Drottning Victorias FrimurarestiftelseNIA NIH HHS P30 AG062422NIA NIH HHS P30 AG066530NIA NIH HHS R01 AG021155NIA NIH HHS R01 AG027161NIA NIH HHS R01 AG062285NIA NIH HHS R35 AG072362NIA NIH HHS U01 AG057195NIH/NIA P30-AG062422Rainwater Charitable FoundationRegionalt Forskningsstöd 2022-1259Skåne University Hospital Foundation 2020-O000028Strategic Research Area MultiParkSwedish Alzheimer Foundation AF-980907Swedish Brain Foundation FO2021-0293Swedish Research Council 2022-00775The Parkinson foundation of Sweden 1412/22
6 · The paper itself

Abstract

introductionTau-positron emission tomography (PET) outcome data of patients with Alzheimer's disease (AD) cannot currently be meaningfully compared or combined when different tracers are used due to differences in tracer properties, instrumentation, and methods of analysis.

methodsUsing head-to-head data from five cohorts with tau PET radiotracers designed to target tau deposition in AD, we tested a joint propagation model (JPM) to harmonize quantification (units termed "CenTauR" [CTR]). JPM is a statistical model that simultaneously models the relationships between head-to-head and anchor point data. JPM was compared to a linear regression approach analogous to the one used in the amyloid PET Centiloid scale.

resultsA strong linear relationship was observed between CTR values across brain regions. Using the JPM approach, CTR estimates were similar to, but more accurate than, those derived using the linear regression approach. DISCUSSION: Preliminary findings using the JPM support the development and adoption of a universal scale for tau-PET quantification. HIGHLIGHTS: Tested a novel joint propagation model (JPM) to harmonize quantification of tau PET. Units of common scale are termed "CenTauRs". Tested a Centiloid-like linear regression approach. Using five cohorts with head-to-head tau PET, JPM outperformed linearregressionbased approach. Strong linear relationship was observed between CenTauRs values across brain regions.

Indexed as

Alzheimer DiseaseBrainPositron-Emission Tomographytau ProteinsAgedCohort StudiesFemaleHumansMaleModels, StatisticalRadiopharmaceuticalsRadiopharmaceuticalstau Proteins[18F]Flortaucipir[18F]GTP1[18F]MK‐6240[18F]PI‐2620[18F]RO948Alzheimer's diseaseCenTauRCentiloidCPADC‐Pathhead‐to‐headImagingPETstandardizationtau

Identifiers

PMID39041435
PMCPMC11497758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.